Company intelligence / Profile preview

Southern Europe New Drug Organization

Ownership: Private
Development stage: Other

Overview

SENDO coordinated and sponsored early-phase oncology clinical trials across multiple tumor types, often in collaboration with academic centers. Notable results include demonstration of safety and preliminary efficacy for combinations such as AP23573 + paclitaxel, with observed partial responses in head & neck and pancreatic cancers. The organization played a significant role in European multi-center studies before ceasing operations around 2010.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

European academic institutionshospitalsTheradex OncologyEarly Clinical Trials Group (ECTG)National Cancer Institute US

Beyond the preview

Go deeper on Southern Europe New Drug Organization.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Southern Europe New Drug Organization.

Explore the full profile